Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 227

Related Citations for PubMed (Select 15778969)

1.

Profiles of HCV core protein and viremia in chronic hepatitis C: possible protective role of core antigen in liver damage.

Carabaich A, Ruvoletto M, Bernardinello E, Tono N, Cavalletto L, Chemello L, Gatta A, Pontisso P.

J Med Virol. 2005 May;76(1):55-60.

PMID:
15778969
2.

Total HCV core antigen assay. A new marker of HCV viremia and its application during treatment of chronic hepatitis C.

Lorenzo J, Castro A, Aguilera A, Prieto E, López-Calvo S, Regueiro B, Pedreira J.

J Virol Methods. 2004 Sep 15;120(2):173-7.

PMID:
15288960
3.

Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA.

Tanaka E, Ohue C, Aoyagi K, Yamaguchi K, Yagi S, Kiyosawa K, Alter HJ.

Hepatology. 2000 Aug;32(2):388-93.

PMID:
10915747
4.

Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.

Fujino T, Nakamuta M, Aoyagi Y, Fukuizumi K, Takemoto R, Yoshimoto T, Miyahara T, Harada N, Sakai H, Nakashima M, Enjoji M.

J Dig Dis. 2009 Feb;10(1):21-5. doi: 10.1111/j.1751-2980.2008.00358.x.

PMID:
19236543
5.

Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity, and liver disease outcome.

Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines C, Herrero M, Carreño V.

Hepatology. 1995 Dec;22(6):1635-40.

PMID:
7489967
6.

Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.

Khattab E, Chemin I, Vuillermoz I, Vieux C, Mrani S, Guillaud O, Trepo C, Zoulim F.

J Clin Virol. 2005 Jun;33(2):150-7. Epub 2004 Dec 18.

PMID:
15911431
7.

Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.

Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Carreño V.

J Med Virol. 2006 Sep;78(9):1190-7.

PMID:
16847959
8.

Long-term evolution of serum and liver viral markers in patients treated for chronic hepatitis C and sustained response.

Moreno M, Pérez-Alvarez R, Rodrigo L, Pérez-López R, Suárez-Leiva P.

J Viral Hepat. 2006 Jan;13(1):28-33.

PMID:
16364079
9.

Quantitative assays for hepatitis C virus in serum as predictors of the long-term response to interferon.

Shiratori Y, Kato N, Yokosuka O, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Ohkubo H, Arakawa Y, Iwama A, Omata M.

J Hepatol. 1997 Sep;27(3):437-44.

PMID:
9314119
10.
11.

Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.

Sasase N, Kim SR, Kim KI, Taniguchi M, Imoto S, Mita K, Hotta H, Shouji I, El-Shamy A, Kawada N, Kudo M, Hayashi Y.

Intervirology. 2008;51 Suppl 1:70-5. doi: 10.1159/000122601. Epub 2008 Jun 10.

PMID:
18544951
12.

Clinical outcome of chronic hepatitis C in patients treated with interferon: comparison between responders and non-responders.

Morisco F, Marmo R, Iasevoli P, Sessa G, Tuccillo C, Del Vecchio Blanco C, Caporaso N.

Ital J Gastroenterol Hepatol. 1999 Aug-Sep;31(6):454-8.

PMID:
10575561
13.

Types of human leukocyte antigen and decrease in HCV core antigen in serum for predicting efficacy of interferon-Alpha in patients with chronic hepatitis C: analysis by a prospective study.

Muto H, Tanaka E, Matsumoto A, Yoshizawa K, Kiyosawa K; Nagano Interferon Treatment Research Group.

J Gastroenterol. 2004 Jul;39(7):674-80.

PMID:
15293139
14.
15.

Relationship between histological prognosis of chronic hepatitis C and amount of hepatitis C virus core protein in serum.

Iijima A, Tanaka E, Kobayashi M, Yagi S, Mizokami M, Kiyosawa K.

J Gastroenterol Hepatol. 2000 Mar;15(3):311-9.

PMID:
10764034
16.

[Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy].

Higashimoto M, Takahashi M, Jokyu R, Saito H.

Rinsho Byori. 2006 Feb;54(2):111-5. Japanese.

PMID:
16548229
17.

Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin.

Fujita N, Kaito M, Kai M, Sugimoto R, Tanaka H, Horiike S, Konishi M, Iwasa M, Watanabe S, Adachi Y.

J Viral Hepat. 2006 Jul;13(7):441-8.

PMID:
16792537
18.

Low HCV replication levels in end-stage hepatitis C virus-related liver disease.

Duvoux C, Pawlotsky JM, Bastie A, Cherqui D, Soussy CJ, Dhumeaux D.

J Hepatol. 1999 Oct;31(4):593-7.

PMID:
10551380
19.

Quantitative liver parameters of HCV infection: relation to HCV genotypes, viremia and response to interferon treatment.

Ballardini G, Manzin A, Giostra F, Francesconi R, Groff P, Grassi A, Solforosi L, Ghetti S, Zauli D, Clementi M, Bianchi FB.

J Hepatol. 1997 Apr;26(4):779-86.

PMID:
9126789
20.

Post-transplant recurrent hepatitis C: immunohistochemical detection of hepatitis C virus core antigen and possible pathogenic implications.

Pessôa MG, Alves VA, Wakamatsu A, Gomes JG, Maertens G, van der Borght B, Kim M, Ferrell L, Wright TL.

Liver Int. 2008 Jul;28(6):807-13. doi: 10.1111/j.1478-3231.2008.01739.x.

PMID:
18422936
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk